KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Liabilities and Shareholders Equity: 2015-2024

Historic Liabilities and Shareholders Equity for BeOne Medicines (ONC) over the last 10 years, with Dec 2024 value amounting to $5.9 billion.

  • BeOne Medicines' Liabilities and Shareholders Equity rose 30.90% to $7.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $25.7 billion, marking a year-over-year increase of 11.63%. This contributed to the annual value of $5.9 billion for FY2024, which is 1.99% up from last year.
  • According to the latest figures from FY2024, BeOne Medicines' Liabilities and Shareholders Equity is $5.9 billion, which was up 1.99% from $5.8 billion recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Liabilities and Shareholders Equity registered a high of $8.5 billion during FY2021, and its lowest value of $5.5 billion during FY2022.
  • For the 3-year period, BeOne Medicines' Liabilities and Shareholders Equity averaged around $5.7 billion, with its median value being $5.8 billion (2023).
  • As far as peak fluctuations go, BeOne Medicines' Liabilities and Shareholders Equity skyrocketed by 247.38% in 2020, and later plummeted by 35.78% in 2022.
  • Over the past 5 years, BeOne Medicines' Liabilities and Shareholders Equity (Yearly) stood at $5.6 billion in 2020, then surged by 52.40% to $8.5 billion in 2021, then slumped by 35.78% to $5.5 billion in 2022, then grew by 5.91% to $5.8 billion in 2023, then climbed by 1.99% to $5.9 billion in 2024.